Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.
OBJECTIVE
To report a case of impending recurrent pterygium treated with topical bevacizumab eyedrops.


METHODS
A 53-year-old woman with impending recurrent pterygium was treated with topical bevacizumab eyedrops (25 mg/mL) administered 4 times daily for 3 weeks. Two months previously, she had undergone excision of a primary ptergyium in the same eye by bare sclera recision and application of mitomycin C.


RESULTS
Treatment with topical bevacizumab for 3 weeks produced prominent regression of limbal-conjunctival neovascularization. At 6-month follow-up, no recurrent pterygium was noted. Symptoms were resolved with no ocular irritation, burning, or any systemic adverse effects.


CONCLUSIONS
These data suggest that off-label short-term use of topical bevacizumab may be effective to prevent recurrence in a patient with impending recurrent pterygium. We believe that this is the first known successful use of topical bevacizumab in such a patient.
Wu
Pei-Chang
PC
Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Kuo
Hsi-Kung
HK
Tai
Ming-Hong
MH
Shin
Shyi-Jang
SJ
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva / Q000098:blood supply*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016850:Limbus Corneae / Q000098:blood supply*; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009883:Ophthalmic Solutions; D011625:Pterygium / Q000150:complications* / Q000473:pathology / Q000601:surgery; D055502:Secondary Prevention; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009883:Ophthalmic Solutions; D000068258:Bevacizumab